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Background. The potential impact of pre-exposure chemoprophylaxis (PrEP) on heterosexual transmission of HIV-1 infection
in resource-limited settings is uncertain. Methodology/Principle Findings. A deterministic mathematical model was used to
simulate the effects of antiretroviral PrEP on an HIV-1 epidemic in sub-Saharan Africa under different scenarios (optimistic,
neutral and pessimistic) both with and without sexual disinhibition. Sensitivity analyses were used to evaluate the effect of
uncertainty in input parameters on model output and included calculation of partial rank correlations and standardized rank
regressions. In the scenario without sexual disinhibition after PrEP initiation, key parameters influencing infections prevented
were effectiveness of PrEP (partial rank correlation coefficient (PRCC)=0.94), PrEP discontinuation rate (PRCC=20.94), level of
coverage (PRCC=0.92), and time to achieve target coverage (PRCC=20.82). In the scenario with sexual disinhibition, PrEP
effectiveness and the extent of sexual disinhibition had the greatest impact on prevention. An optimistic scenario of PrEP with
90% effectiveness and 75% coverage of the general population predicted a 74% decline in cumulative HIV-1 infections after
10 years, and a 28.8% decline with PrEP targeted to the highest risk groups (16% of the population). Even with a 100% increase
in at-risk behavior from sexual disinhibition, a beneficial effect (23.4%–62.7% decrease in infections) was seen with 90%
effective PrEP across a broad range of coverage (25%–75%). Similar disinhibition led to a rise in infections with lower
effectiveness of PrEP (#50%). Conclusions/Significance. Mathematical modeling supports the potential public health
benefit of PrEP. Approximately 2.7 to 3.2 million new HIV-1 infections could be averted in southern sub-Saharan Africa over 10
years by targeting PrEP (having 90% effectiveness) to those at highest behavioral risk and by preventing sexual disinhibition.
This benefit could be lost, however, by sexual disinhibition and by high PrEP discontinuation, especially with lower PrEP
effectiveness (#50%).
Citation: Abbas UL, Anderson RM, Mellors JW (2007) Potential Impact of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in Resource-Limited
Settings. PLoS ONE 2(9): e875. doi:10.1371/journal.pone.0000875
INTRODUCTION
While the search is ongoing for a safe and effective HIV-1 vaccine,
encouraging data from animal studies [1–5] have ignited interest
in pre-exposure chemoprophylaxis (PrEP) with antiretrovirals as
a strategy to prevent HIV-1 infection [6]. The potential impact of
targeted or widespread PrEP on HIV-1 epidemics is uncertain and
major determinants of its utility have not been defined. Several
clinical trials to address the efficacy of PrEP are underway, but
these will take considerable time to complete and will not
specifically address the potential public health benefit [7,8]. We
therefore developed a mathematical model of a heterosexual HIV-
1 epidemic and analyzed the potential for HIV-1 prevention from
PrEP under different scenarios of effectiveness, duration of use,
population coverage, emergence and spread of drug resistance and
increased sexual risk behavior.
METHODS
Model Structure
We refined our previously described deterministic mathematical
model of HIV-1 disease progression and heterosexual transmission
by incorporating demographic and sexual behavioral details, and
by the introduction of PrEP [9]. Briefly, the model population was
stratified according to gender, age, sexual activity level, disease
state, PrEP status, and HIV-1 drug resistance. Model input
parameters were chosen to simulate a mature epidemic in
southern sub-Saharan Africa. Parameter assignments were made
from recent literature on HIV-1 disease progression [10,11],
infectivity [12], and sexual behavior [13–15]. The model consists
of coupled nonlinear differential equations describing the
population and epidemiological stratifications outlined in
Figure 1. Model parameters are shown in Tables 1 and 2, and
model equations and details are provided in the Appendix S1.
Model Output and Introduction of PrEP
The model’s dynamical behavior was investigated using numerical
methods. The key model outputs were: HIV-1 prevalence; HIV-1
incidence; cumulative new HIV-1 infections; and cumulative
deaths from AIDS. PrEP was introduced (as once daily oral
antiretroviral dosing) at endemic equilibrium when HIV-1
prevalence in sexually active adults (15–49 year-olds) was
approximately 20%. The implementation of PrEP was simulated
both in the absence and presence of sexual disinhibition of the
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PLoS ONE | www.plosone.org 1 September 2007 | Issue 9 | e875individuals on PrEP, where disinhibition is defined as increased
rate of sex partner change. We summed over 20 years of PrEP
implementation the number of new infections and the total
number of persons on PrEP, to make comparisons between the
epidemics with and without PrEP at each simulation time-step.
The key output variables employed in these comparisons were: the
% change in the cumulative new HIV-1 infections; the ratio of
HIV-1 infections prevented to person-years of PrEP; the ratio of
HIV-1 infections prevented to persons enrolled in PrEP; and the
ratio of the cost of PrEP to the number of infections prevented.
Effectiveness of PrEP
Our model represents the transmission of HIV-1 as a Poisson
process [16–18]. The probability of transmission per heterosexual
partnership, b, between an individual (on PrEP) of gender g,
activity level k, and age i, with an (infected) individual of opposite
gender g9, activity level l and age j is given by:
b
VH
g0lj~1{ 1{cVH
g0lj 1{jh ðÞ
no Ygg0klij
where Y is the number of sex acts within the partnership; c is the
probability of HIV-1 transmission per sex-act (infectivity) based on
the disease stage, V, and drug resistance status, H, of the infected
partner; and jh is the effectiveness of PrEP. Effectiveness is defined
as the probability of preventing HIV-1 transmission per sex-act
through PrEP and is given by the product of the average efficacy
of PrEP, j (the degree of protection provided, from HIV-1
transmission per sex-act) and the average level of adherence to
PrEP, h (assuming once daily dosing and that doses are missed at
random). In a partnership, where the infected partner harbors
major drug-resistant variants (discussed below), the probability of
transmission of resistant virus is ub, while that of wild-type virus is
(12u)b, and the effectiveness of PrEP against resistant virus is ijh.
The parameters j, h, u and i assume values between 0 and 1
(Table 2).
Modeling Drug Resistance
We sub-classified the HIV-1 infected individuals based on their
PrEP status (naı ¨ve, on or off), type of drug resistance (primary or
secondary), and simplified population dynamics of drug-resistant
HIV-1 (persistence or reversion), to represent the individuals’ drug
resistance status (Figure 1 and Table 2). Our model assumptions
for HIV-1 drug resistance are as follows. In an infected individual,
the HIV-1 population is comprised of a set of related variants,
termed as viral quasispecies [19]. Before the introduction of PrEP,
all HIV-1 infected individuals harbor a dominant population of
wild-type (drug-sensitive) virus [20]. Drug-resistant mutants are
selected by drug pressure in a fraction (termed selection, p, having
a value between 50% to 100%) of those individuals who become
Figure 1. Simplified Flow Diagram of Model with PrEP Implementation.
doi:10.1371/journal.pone.0000875.g001
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mutants with: K65R with tenofovir [21–23]; M184V with
emtricitabine [24]; and M184V+K65R with tenofovir+emtricita-
bine [25,26]). This type of resistance is termed secondary
resistance [27]. A proportion of susceptible individuals, both on
and not on PrEP, become infected by drug-resistant mutants
through transmission from their sexual partner. This type of
resistance is termed primary resistance [27]. Upon removal of
selection pressure, either by discontinuation of PrEP [23] or
transmission to a drug naı ¨ve individual [28], the drug-resistant
mutants decline after a period of persistence, due to outgrowth by
wild-type virus (reversion) [29–31]. Prior to reversion, the drug-
resistant mutants are the dominant (major) viral variants [20,32],
whereas following reversion these become minor variants [32,33].
Compared to individuals with wild-type virus, individuals with
drug-resistant variants can have: i) decreased probability of
transmission per sex act (infectivity, c
VH, having a relative value
of 50% to 100%) due to lower level viremia from PrEP use [23,24]
or from diminished viral replicative fitness [34–36]; and ii)
decreased viral transmission fitness (probability per partnership
that a resistant rather than wild-type virus will be transmitted, u,
with a value between 20% to 100%) [37–39]; but the same rate of
disease progression due to temporary predominance of drug-
resistant mutants. Individuals with minor drug-resistant variants
behave as individuals with wild-type virus in terms of infectivity
and disease progression and likewise do not transmit drug resistant
mutants. The re-emergence of major variants due to subsequent
drug challenge (e.g. antiretroviral therapy) [40,41] was not modeled.
Sensitivity Analyses
We performed sensitivity analyses [42] to determine the relative
influence of PrEP-related model input parameters (Table 2) on the
predicted decrease in new infections. For multivariate time-
dependent sensitivity analyses, we rank transformed input and
output data obtained using Latin hypercube sampling [43,44] and
1000 simulation runs for epidemic scenarios with and without
sexual disinhibition, and from this derived partial rank correlation
coefficients (PRCCs) and standardized rank regression coefficients
(SRRCs) [45,46].
PrEP Scenarios
The impact of PrEP was determined by simulating three different
scenarios: namely, optimistic, neutral and pessimistic (Table 2).
For each of these scenarios, we simulated: i) the implementation of
PrEP in the sexually active population in general (non-targeted
strategy); ii) PrEP targeted to the two highest sexual activity levels
(targeted-by-activity strategy); and iii) PrEP initiation targeted to
the group 15–20 years of age (targeted-by-age strategy). We
performed univariate sensitivity analysis for each scenario, in
which we measured the change in infections arising from variation
of each PrEP-related input parameter over its specified range
Table 1. Model Parameters for the Simulated HIV-1 Epidemic
..................................................................................................................................................
PARAMETER SYMBOL VALUE UNIT REFERENCE
Epidemiological
Average Duration of HIV-1 Disease by Stage of Infection*
Recent 1/v
1 0.5 year [12]
Chronic 1/v
2 7.5 year [10,11]
AIDS 1/v
3 2.0 year [10,11]
HIV-1 Infectivity by Stage of Infection*
Recent c
1 0.0082 per act [12]
Chronic c
2 0.0010 per act [12]
AIDS c
3 0.0036 per act [12]
Behavioral
Average rate of sexual partner change c 2 per year [13,15]
Average number of sex acts per partnership for sexual activity levels 1 to 4
U Y 9, 23, 44, 120 per partner per year [12,53]
Assortativeness of mixing by age W1 0.75 [63]
Assortativeness of mixing by sexual activity level W2 0.75 [63]
Degree of preference for partner with 10 years age difference W3 0.5 [63]
Proportion of adult males in sexual activity levels 1 to 4 0.044, 0.089, 0.195, 0.672 [13–15]
Proportion of adult females in sexual activity levels 1 to 4 0.002, 0.026, 0.147, 0.825 [13–15]
Ratio of rates of sexual partner acquisition by activity level 1 to 4 100 : 65 : 5 : 1 [13–15,63]
Ratio of rates of sexual partner acquisition by age group 1 to 7 2 : 4 : 6 : 8 : 5: 3 :1 [63]
Average duration of sexual activity 35 year [13–15,63]
Demographic
Initial population size U 5.7610
6 person [72]
Initial life expectancy for males and females 1/m 49 and 53 year [72]
Total fertility rate 6.8 births per female [72]
Sex ratio at birth 1 [63,72]
*The superscripts represent the disease stage.
UIndividuals with AIDS were assumed to be sexually inactive during the last 6 months of their life [12,81,82].
doi:10.1371/journal.pone.0000875.t001
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PLoS ONE | www.plosone.org 4 September 2007 | Issue 9 | e875(Table 2). We also analyzed the interplay between key PrEP-
related input parameters and the number of infections prevented.
Finally, we estimated the potential reduction in the number of new
adult infections in all of southern sub-Saharan Africa, by
extrapolating our results to current epidemiological data from
that region [47].
Software: Model construction, simulations and sensitivity runs
were implemented concurrently in Berkeley Madonna (version
8.3.8; Robert I. Macey and George F. Oster) and Vensim DSS
(version 5.5d; Ventana Systems, Inc.). Data were analyzed using
Microsoft Excel (version 11.8; Microsoft Corporation) and Stata
SE (version 9.2; StataCorp LP).
RESULTS
Our mathematical model stratifies the population based on
gender, age, sexual activity level, disease state, PrEP status, and
HIV-1 drug resistance (Figure 1), and its dynamical behavior is
analyzed numerically. We introduced PrEP at endemic equilibri-
um and simulated optimistic, neutral and pessimistic scenarios
(Table 2). For each scenario we simulated three strategies of PrEP
implementation: i) in the sexually active population in general
(non-targeted strategy); ii) in the two highest sexual activity levels
(targeted-by-activity strategy); and iii) in the group15–20 years of
age (targeted-by-age strategy). Each strategy was simulated both
with and without sexual disinhibition of the individuals on PrEP.
To determine the epidemiological impact of PrEP, we compared
the epidemics with and without PrEP up to 20 years and
determined the % change in the cumulative new HIV-1 infections;
the ratio of HIV-1 infections averted to person-years of PrEP; the
ratio of HIV-1 infections averted to persons enrolled in PrEP; and
the ratio of the cost of person-years of PrEP to the number of
infections averted.
In the simulated epidemic, adult HIV-1 prevalence was 20% at
endemic equilibrium with the ratio of female to male prevalence of
1.66 [48]. Simulated trends in female prevalence are shown in
Figure 2. They mimic observed patterns among urban antenatal
clinic attendees in Zambia [49].
The results for both univariate and multivariate sensitivity
analyses of the predicted impact of PrEP were similar, thus only
multivariate results are presented. Table 3 shows sensitivity
analyses of the predicted decline in cumulative new HIV-1
infections for 20 years after PrEP implementation. In general,
coefficient (PRCC and SRCC) values near 1 indicate a strong
positive influence of the input variable on prevention of infections,
whereas values near -1 indicate a strong negative influence. Values
near 0 indicate little, if any, influence [50]. In the scenario without
sexual disinhibition occurring, the rate of PrEP discontinuation
(inverse of the average duration of PrEP use) was the strongest
determinant overall of reduction in infections and its effect
persisted over time (PRCC ranged from 20.94 at year 5 to 20.97
at year 20). The next most important determinants were the
effectiveness of PrEP (composite of efficacy and adherence) and
the fraction of individuals covered (coverage) by PrEP (PRCCs of
0.92 and 0.88 at year 10, respectively), with both parameters
Figure 2. Trends in HIV-1 Prevalence among Urban Antenatal Clinic Attendees in Zambia from 1994 to 2004 [49] and the Simulated Adult
Female Population.
doi:10.1371/journal.pone.0000875.g002
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PLoS ONE | www.plosone.org 5 September 2007 | Issue 9 | e875having a positive influence. The time to achieve target coverage
had a strong negative influence on infections prevented at year 5
(PRCC of 20.82), which declined over long durations of time. A
weak negative influence (PRCC of 20.13) was seen for secondary
drug resistance (resistance developing on PrEP), though this
persisted over time.
In the scenario in which sexual disinhibition occurred among
individuals on PrEP, the effectiveness of PrEP emerged as the
strongest positive determinant of infections prevented with
a PRCC ranging from 0.87 to 0.91. The increase in at-risk
behavior was the strongest negative determinant of infections
prevented having a PRCC of 20.75 at year 10. Though PrEP
discontinuation rate and coverage remained significant with
disinhibition scenario, their effect was attenuated on average by
about 33% and 50%, respectively, compared to the scenario
without disinhibition.
SRRC values confirmed the above findings. In the absence of
sexual disinhibition, the influence on infections prevented was
strongest for the rate of PrEP discontinuation (SRRC range:
20.56 to 20.81) followed by effectiveness (SRRC range: 0.44 to
0.56) and coverage (SRRC range: 0.34 to 0.49). With sexual
disinhibition (SRCC of 20.42), the effectiveness of PrEP became
the predominant influence on the infections prevented (SRRC
range: 0.71 to 0.76).
Table 4 compares the outcomes in the optimistic, neutral and
pessimistic scenarios 10 years after the introduction of PrEP.
These scenarios respectively assume optimistic, neutral and
pessimistic sets of PrEP-related input parameters in Table 2.
The potential impact of PrEP was impressive for the optimistic
scenario, but was negligible for the pessimistic scenario, illustrating
the importance of key chemoprophylaxis parameters on outcome.
For each scenario, the greatest decline in infections was achieved
with the non-targeted strategy, whereas the lowest cost of PrEP per
infection averted was obtained with the targeted-by-activity
strategy. Specifically, a 74% reduction in infections occurred for
the optimistic scenario, 24.9% for the neutral scenario and 3.3%
for the pessimistic scenario with the non-targeted strategy. These
figures declined to 28.8%, 6.8% and 0.8%, respectively, with the
targeted-by-activity strategy. However, the cost of person-years of
PrEP per infection averted over the 10 year intervention time span
fell substantially with the targeted strategy; from $6,812 to $638
for the optimistic scenario, from $9,629 to $ 1,160 for the neutral
scenario, and from $20,164 to $2,949 for the pessimistic scenario.
The targeted-by age strategy yielded intermediate declines in
infections (45.5%, 14.5% and 2.0%), although the cost of person-
years of PrEP per infection averted remained high ($5,723, $8,968
and $20,202). Overall, the numbers of infections averted per
person-year of PrEP and per person enrolled in PrEP were highest
for the optimistic targeted-by-activity strategy (0.33 and 1.74).
Similar results were seen after 20 years of PrEP (data not shown).
Sexual disinhibition of individuals on PrEP progressively eroded
the declines in infections for all scenarios (Table 4), although this
effect was modest for the optimistic scenario. Specifically, at year
10 in the optimistic scenario with a 100% increase in at-risk
behavior, the decline in infections was 62.7% for the non-targeted
strategy and 17.7% for the targeted-by activity strategy (reduced
from 74% and 28.8%, respectively, without disinhibition). The
infections increased by 1.9% for the neutral scenario with
targeted-by activity strategy, and increased by 7%, 2.5% and
4.4% for the three pessimistic scenario strategies (non-targeted,
targeted by sexual activity and targeted by age group). Such
increases were also seen with the optimistic scenario when lower
levels of effectiveness were assumed. For example, at 50%
effectiveness, infections increased by 8% for the non-targeted
strategy as the result of a 100% increase in at-risk behavior
(Figure 3). With sexual disinhibition, the decline in infections was
also influenced negatively by the infectivity of individuals with
secondary resistance and the probability of transmission of
resistant virus from individuals with secondary resistance;
however, these effects were weak with PRCCs of 20.16 and
Table 3. Results of Sensitivity Analyses for Model Parameters Affecting the Decrease in Cumulative New HIV-1 Infections (%)
..................................................................................................................................................
PARAMETER NO SEXUAL DISINHIBITION SEXUAL DISINHIBITION
Year 5 Year 10 Year 15 Year 20 Year 5 Year 10 Year 15 Year 20
PARTIAL RANK CORRELATION COEFFICIENTS*
Effectiveness of PrEP against sensitive virus 0.94 0.92 0.91 0.89 0.91 0.89 0.88 0.87
Fraction of individuals enrolled into PrEP 0.92 0.88 0.86 0.84 0.54 0.45 0.41 0.40
Probability of transmission of resistant virus from Y
R99 { 20.07 20.08 20.08 20.07
Infectivity of Y
R99 { 20.13 20.13 20.14 20.14 20.16 20.16 20.16 20.17
Time period to achieve target coverage 20.82 20.13 20.36
PrEP permanent discontinuation rate 20.94 20.96 20.97 20.97 20.58 20.66 20.67 20.67
Increase in sexual risk behavior 20.77 20.75 20.74 20.73
STANDARDIZED RANK REGRESSION COEFFICIENTS*
Effectiveness of PrEP against sensitive virus 0.56 0.50 0.46 0.44 0.76 0.74 0.72 0.71
Fraction of individuals enrolled into PrEP 0.49 0.39 0.35 0.34 0.22 0.19 0.18 0.17
Probability of transmission of resistant virus from Y
R99 { 20.02 20.03 20.03 20.03
Infectivity of Y
R99 { 20.03 20.03 20.03 20.03 20.06 20.06 20.06 20.07
Time period to achieve target coverage 20.30 20.03 20.13
PrEP permanent discontinuation rate 20.56 20.75 20.79 20.81 20.24 20.32 20.35 20.36
Increase in sexual risk behavior 20.42 20.42 20.42 20.43
*The p-value is 0.0000 except for where the p-value , 0.05.
{Y
R99 represents individuals with secondary resistance.
doi:10.1371/journal.pone.0000875.t003
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PLoS ONE | www.plosone.org 6 September 2007 | Issue 9 | e87520.08, respectively, at year 10 (Table 3). Other input parameters
related to drug-resistance (Table 2) were not significantly
associated with outcome.
Table 5 quantifies the predicted impact of PrEP for selected
countries in southern Sub-Saharan Africa, as well as for the overall
region, where the median country-prevalence of HIV-1 is about
20% [47]. In South Africa, up to 1.5 million new HIV-1 infections
could be averted over 10 years by PrEP coverage of 75% of high
sexual activity groups [51]. The corresponding estimate of the
infections averted for Zambia is 0.36 million, for Botswana 0.13
Figure 3. Contour Graph for Decline in Cumulative Infections (%) as a Function of Effectiveness of PrEP and Increase in Risk Behavior Assuming
Optimistic Scenario. Negative numbers reflect increase in infections.
doi:10.1371/journal.pone.0000875.g003
Table 4. Outcomes for Optimistic, Neutral and Pessimistic Scenarios after Ten Years of PrEP Implementation
..................................................................................................................................................
Outcome Non-Targeted Targeted by Sexual Activity Targeted by Age Group
Optimistic Neutral Pessimistic Optimistic Neutral Pessimistic Optimistic Neutral Pessimistic
Decline in Cumulative New HIV-1 Infections (%) 74.0 24.9 3.3 28.8 6.8 0.8 45.5 14.5 2.0
Decline in Cumulative New HIV-1 Infections (%);
r=2
{
62.7 1.3 27.0 17.7 21.9 22.5 36.5 0.1 24.4
Infections Averted per Person-Year of PrEP 0.03 0.02 0.01 0.33 0.18 0.07 0.04 0.02 0.01
Infections Averted per Person Enrolled in PrEP 0.21 0.11 0.03 1.74 0.62 0.15 0.21 0.10 0.03
Cost of Person-Years of PrEP per Infection
Averted($)
"
22,918 32,398 67,842 2,147 3,904 9,923 19,254 30,173 67,970
Cost of Person-Years of PrEP per Infection
Averted($)
1
10,397 14,697 30,776 974 1,771 4,502 8,734 13,688 30,834
Cost of Person-Years of PrEP per Infection
Averted($)
{
6,812 9,629 20,164 638 1,160 2,949 5,723 8,968 20,202
{Assuming a 100% increase in at-risk behavior.
"Assuming $700 per person-year of PrEP; the market price of a generic version of tenofovir (Tenvir) manufactured by Cipla in India [87].
1Assuming $318 per person-year of PrEP ($0.87/day); the current cost of manufacturing tenofovir+emtricitabine (Truvada) by Gilead [88].
{Assuming $208 per person-year of PrEP ($0.57/day); the current cost of manufacturing tenofovir (Viread) by Gilead [88].
Costs (defined as drug costs per person-year of PrEP) and health benefits (infections averted) are presented in their undiscounted form for clarity [80]. Costs of PrEP
exclude all other costs e.g. drug distribution, pharmacy and clinical services, communications and education, laboratory, treatment of complications including
resistance, and counseling. Analyses also exclude the consequences of HIV-1 infection including costs of provision of antiretroviral therapy.
doi:10.1371/journal.pone.0000875.t004
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PLoS ONE | www.plosone.org 7 September 2007 | Issue 9 | e875million and for Lesotho 0.09 million. For southern sub-Saharan
Africa as a whole up to 3.2 million new HIV-1 infections could be
averted over 10 years at a cost of roughly $2.0 billion for PrEP. All
these estimates assume high levels of efficacy and adherence to
PrEP.
DISCUSSION
Data from animal studies show that systemic antiretrovirals can
prevent infection of macaques by simian immunodeficiency virus
[1,3–5]. The safety and efficacy of once daily oral antiretroviral
PrEP in humans are under clinical trials in the Unites Sates, Latin
America, Africa and Asia [7,8]. However, these studies are not
designed to address the population-level impact of PrEP on rates
of HIV-1 transmission over many years. Using a carefully stratified
and well-parameterized deterministic model of HIV-1 trans-
mission, our analyses suggest that PrEP could have a profound
impact on the HIV-1 epidemic, if effectiveness is high (high levels
of efficacy and adherence) and usage persists over a decade or
more; that is over much of the typical duration of sexual activity of
an individual. Though the maximum effect of PrEP was observed
at the highest level of coverage (75% of susceptible sexually active
individuals) with good continuous adherence, such coverage and
adherence are not realistic. Furthermore, the cost of untargeted
PrEP per infection prevented is relatively high at $6,812. PrEP
targeted to persons with greatest sexual activity produced
significant declines in infections and had the lowest cost of
person-years of PrEP per infection averted at $638. This result is
noteworthy for two reasons: the highest activity groups comprised
only 13.3% and 2.8% of the male and female model populations;
and PrEP was introduced at endemic equilibrium when these high
activity groups become saturated and play a lesser role in the
spread of HIV-1 compared to earlier stage epidemics [52]. Models
of HIV-1 vaccine implementation have also suggested that
targeting by sexual activity could have a significant epidemiolog-
ical impact [53]. In contrast to these vaccine models, we found
that targeting by age group had less of an impact than a non-
targeted approach and very similar estimates of cost of person-
years of PrEP per infection averted. This is because, unlike the
assumption of a one time (6 booster) vaccination, PrEP requires
continual use in the presence of ongoing risk of sexual trans-
mission.
Sensitivity analyses showed that the effectiveness of PrEP was
the most important determinant of the magnitude of decline in
infections. This is especially the case in the scenario with sexual
disinhibition of the individuals on PrEP. The high effectiveness
assumed in the optimistic scenario was also the foremost reason
why this scenario yielded the best outcomes overall, including cost
of person-years of PrEP per infection averted. When effectiveness
was lower, infections increased for all scenarios with increased risk
taking behaviors of those on PrEP. The decline in infections was
also very sensitive to the PrEP discontinuation rate (inverse of the
average duration of PrEP use) and the level of coverage. We
modeled the PrEP discontinuation rate as distinct from adherence,
which was represented within our composite parameter of
effectiveness. Our data suggest that continual access to PrEP
would be of great importance and permanent discontinuation
would undermine the epidemiological gains if PrEP use was short-
lived in relation to individuals’ typical duration of sexual activity.
Our representation of the evolution and transmission of drug
resistance is crude. Further model development is required in this
area and will be the subject of additional study. Nevertheless, the
parameters directly related to drug resistance did not emerge as
key determinants of the outcome of PrEP. These results may be
explained by a greater contribution of other parameters impacting
HIV-1 transmission, such as PrEP effectiveness.
The feasibility of PrEP as an HIV-1 prevention strategy would
not only depend on its safety and efficacy, but also on its
incremental cost-effectiveness compared to other intervention
strategies in resource-poor settings. Our simple comparison
between implementation of PrEP to a ‘‘do nothing’’ strategy
revealed that the cost of person-years of PrEP per infection averted
for the optimistic scenario with targeted-by-activity strategy of
$638–$2147, compared favorably with the projected cost of $3900
per infection averted over the period 2005–2015 with the
UNAIDS comprehensive prevention package [54]. This same
study projected a savings of $4700 in forgone treatment and care
costs. Using mathematical models, other investigators have
reported that PrEP is a cost-effective strategy among high-risk
men who have sex with men in New York City [55], and among
populations in low-income settings [56].
Sub-Saharan Africa has about 63% of the HIV-infected
population of the world totaling 22.4 million adults [47,57].
Table 5. Potential Impact of PrEP Introduced in 2007 on HIV-1 Infections in Southern Sub-Saharan Africa
{"
..................................................................................................................................................
Region/Country
Baseline Adult
HIV Prevalence %
Baseline Adult
HIV Incidence %
Baseline Adult
Population people
Population
Growth Rate %
Cumulative New HIV Infections Averted after
10 Years
Optimistic Scenario & Targeted by Sexual
Activity
No Disinhibition 100% Disinhibition
Lesotho 23.2 4.8 865 000 0.1 92 710 56 942
Botswana 24.1 6.7 909 000 0.1 132 870 81 608
Zambia 17.0 2.6 5 281 000 1.7 361 132 221 803
South Africa 18.8 2.4 25 204 000 0.8 1 477 691 907 581
Southern Sub-Saharan Africa
1 19.6
{ 54 886 000 2 713 746–3 166 037 1 666 752–1 944 544
{These are conservative projections based on estimates of the size of adult population [47,71] and assuming constant incidence [73–75,89], prevalence [47] and growth
rate [47].
"For southern sub-Saharan Africa overall, projections are based on the UNAIDS/WHO statement that the total number of infections in this region were 1.1 million for
three consecutive years including 2005 [75]. With this estimate as a constant, low projection assumes 86% of these infections occur in adults, while the high projection
assumes the full estimate.
1Excludes Angola, Madagascar, Mauritius and Seychelles.
{Refers to median country-prevalence.
doi:10.1371/journal.pone.0000875.t005
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PLoS ONE | www.plosone.org 8 September 2007 | Issue 9 | e875Though epidemics of various characteristics are affecting this
region [58], the vast majority of the population are not yet infected
with HIV-1 and thus effective prevention strategies are urgently
needed. Our analyses indicate that approximately 2.7 to 3.2 million
new HIV-1 infections could be averted in southern sub-Saharan
Africaoverthe next10 yearsbytargetingPrEPto population groups
with the highest sexual activity concomitant with preventing
increased risk behaviors in those on PrEP. It is not always easy,
however, to identify those with high sexual activity patterns, except if
they are involved in commercial sexual activities [14,59].
The estimate of the number of infections averted for South
Africa alone is 1.5 million infections. This high individual and
public health benefit will require sustained access to PrEP. In
addition, the integration of PrEP programs with voluntary
counseling and testing services and other prevention programs
(e.g. promotion of condom use, circumcision, and identification
and treatment of sexually transmitted diseases (STDs) will be key
in controlling spread of HIV-1) [60].
There are some important limitations of our current model
structure and the assumptions embedded within it. The precise
quantitative detail of our predictions will be affected by variations
in the structure and sexual activity patterns of different popula-
tions, for which data are very limited, especially on sexual mixing
patterns. However, we employed a well-established template of
sexual behavior [61–65], with robust epidemiological and de-
mographic parameterization, broadly applicable to southern sub-
Saharan Africa. The actual impact of PrEP will depend on the
PrEP agent or agents used as well as the physiological, behavioral
and viral characteristics of the HIV-1 infected target population.
Primate studies of PrEP suggest superiority of tenofovir plus
emtricitabine over tenofovir alone [1,2]. Natural polymorphisms
in HIV-1 subtypes have been postulated to play an important role
in drug resistance pathways [66], including the propensity of HIV-
1 subtype C virus that is predominant in Sub-Saharan Africa [67],
for more frequent and rapid development of the K65R tenofovir-
resistance mutation, noted by some investigators [68,69] though
not by others [70]. Although there is substantial uncertainty
regarding PrEP-related parameters, we employed wide ranges
(within plausible bounds) for our input parameters and performed
extensive sensitivity analyses. There are significant differences
between the demographic and HIV/AIDS epidemiological trends
estimates predicted by different agencies, largely as a result of the
methods employed in analysis and prediction [15,47,71,72]. In
addition, except for South Africa [73], estimates of HIV-1
incidence have not been measured directly at the population level
in most African countries, and reliable country-specific estimates
are rarely available excepting from a few well-defined study sites
with long term surveillance [74]. We elected to employ the
demographic and HIV/AIDS epidemiological estimates from
UNAIDS where applicable [47,71,75]. Our optimistic analyses
assume a high level of effectiveness for PrEP, which may not be the
case because of more limited drug activity and/or medication
adherence. However, data on both efficacy of the potential PrEP
agents [1], and adherence in Africa [76] justify some degree of
optimism. In a macaque study [1] in which animals received
weekly rectal simian human immunodeficiency virus challenges,
83% (5/6) of the controls became infected after 14 challenges,
whereas 100% (6/6) of the macaques that received subcutaneously
a combination of 22 mg tenofovir and 20 mg emtricitabine per kg
once daily remained uninfected . A meta-analysis [76] of 31 North
American studies (17,573 patients total) indicated a pooled
estimate of 55% of the populations achieving adequate levels of
adherence, whereas analysis of 27 African studies (12,116 patients
total) indicated a pooled estimate of 77%. About 71% of the
former and 66% of the latter studies used patient self-report to
assess adherence and similar thresholds for adherence monitoring
(.80% to 100%). The authors concluded that although adherence
remained a concern in North America, favorable levels of
adherence could be achieved in sub-Saharan Africa.
We excluded from our analyses the impact of antiretroviral
therapy for infected persons [9], various other influences on
transmission (e.g. STDs [77,78], circumcision [79] and condom
use [16]), as well as a formal cost-effectiveness analysis [80]. These
and other refinements will be addressed in future work. Neverthe-
less, the key conclusion of this study is that PrEP can be a cost
effective intervention given high efficacy, good adherence and
long-term use, especially if sexual disinhibition is prevented.
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